文献速递免疫规划妇幼与学校卫生慢病防控与筛查

瑞典学校人乳头瘤病毒疫苗接种计划中精神疾病与神经发育状况对接种率的影响:一项基于人群的队列研究

The role of mental illness and neurodevelopmental conditions in human papillomavirus vaccination uptake within the Swedish school-based vaccination programme: a population-based cohort study.
PubMed 文献 · Lancet Public Health · 2024-01-01

该研究基于瑞典学校人乳头瘤病毒(HPV)疫苗接种计划,纳入2002年1月1日至2004年3月1日出生的115 104名女孩,分析个人及父母精神疾病和神经发育状况与HPV疫苗第一剂和第二剂接种的关系。结果显示,有精神健康状况的女孩第一剂接种率较低(调整相对风险0·89),自闭症和智力障碍关联最强,第二剂接种率与精神健康状况无强关联。

要点

  • 有精神健康状况的女孩HPV疫苗第一剂接种率较低(调整相对风险0·89)。
  • 自闭症(0·79)或智力障碍(0·78)与第一剂接种率降低关联最强。
  • 第二剂接种率95·0%,与女孩或父母精神健康状况无强关联。

核心结论

  • 有精神健康状况的女孩在宫颈癌预防方面存在差异,呼吁进一步研究以确保公平保护。

研究设计与样本

  • 基于瑞典学校HPV疫苗接种计划的全国性基于人群的队列研究,纳入2002年1月1日至2004年3月1日出生、有资格接种两剂疫苗的女孩115 104名,使用多变量泊松回归模型分析。

主要发现

  • 2211名女孩(1·9%)有专科诊断的任何精神健康状况。
  • 第一剂HPV疫苗接种率为80·7%(92 912/115 104),有vs无任何精神健康状况的女孩调整相对风险为0·89(95%CI 0·87-0·91)。
  • 自闭症(0·79[95%CI 0·75-0·85])或智力障碍(0·78[95%CI 0·73-0·83])与第一剂接种率降低关联最强。
  • 有vs无处方使用精神药物的女孩接种率较低(0·93[95%CI 0·92-0·95]),抗精神病药关联最强(0·68[95%CI 0·56-0·82])。
  • 第二剂接种率为95·0%(88 308/92 912),与女孩或父母精神健康状况无强关联。

关键数值与推荐

  • 第一剂HPV疫苗接种率80·7%(92 912/115 104),有vs无任何精神健康状况调整相对风险0·89(95%CI 0·87-0·91)。
  • 自闭症调整相对风险0·79(95%CI 0·75-0·85),智力障碍0·78(95%CI 0·73-0·83)。
  • 有vs无处方精神药物调整相对风险0·93(95%CI 0·92-0·95),抗精神病药0·68(95%CI 0·56-0·82)。
  • 第二剂接种率95·0%(88 308/92 912),与精神健康状况无强关联。

临床怎么用

  • 原文结论指出有精神健康状况的女孩在宫颈癌预防方面存在差异,呼吁进一步研究以确保公平保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite documented mental illness-related disparities in cervical cancer screening and incidence, insufficient data exist on differences in cervical cancer prevention strategies, such as human papillomavirus (HPV) vaccination. We aimed to investigate the association of mental illness and neurodevelopmental conditions among girls and their parents with uptake of HPV vaccination in Sweden. METHODS: This population-based cohort study was based on the Swedish school-based HPV vaccination programme, which offers the first vaccine dose to girls aged 10-13 years, with a second dose offered within 12 months. We identified all girls born between Jan 1, 2002, and March 1, 2004, using the Swedish Total Population Register-ie, those eligible for two vaccine doses in the vaccination programme from its initiation in autumn 2012, to March, 2019. Nationwide Swedish register data (National Patient Register, Prescribed Drug Register, HPV Vaccination Register, National Vaccination Register, Total Population Register, Multi-Generation Register, Longitudinal Integrated Database for Health Insurance and Labour Market Studies, Education Register, National Cervical Screening Registry, and Cancer Register) were used to define individual and parental mental health conditions, including mental illness and neurodevelopmental conditions (defined by a clinical diagnosis and prescribed psychotropic medication use), HPV vaccine uptake (first and second dose), and sociodemographic and clinical characteristics. The two outcomes were uptake of the first HPV vaccine dose by the girl's 14th birthday and uptake of the second dose by the 15th birthday in relation to individual and parental mental health conditions, calculated using multivariable Poisson regression models. FINDINGS: 115 104 girls were included in the study population. 2211 girls (1·9%) had a specialist diagnosis of any mental health condition. Uptake of the first HPV vaccine dose was 80·7% (92 912 of 115 104) and was lower among girls with versus without any mental health condition (adjusted relative risk 0·89 [95% CI 0·87-0·91]). The diagnosis of autism (0·79 [0·75-0·85]) or intellectual disability (0·78 [0·73-0·83]) were most strongly associated with lower HPV vaccine uptake. Vaccine uptake was also lower among girls with versus those without prescribed use of psychotropic medication (0·93 [0·92-0·95]), with the strongest association observed for antipsychotics (0·68 [0·56-0·82]). Uptake of the second dose was 95·0% (88 308 of 92 912), with no strong associations between uptake and mental health conditions in girls or their parents. INTERPRETATION: Our findings suggest disparities in cervical cancer prevention among girls with mental health conditions, and call for further research to ensure equitable protection. FUNDING: Swedish Cancer Society.

来源:Lancet Public Health,查看原文。版权归原作者所有。

引用

  1. Hu K, Barker MM, Herweijer E, et al. The role of mental illness and neurodevelopmental conditions in human papillomavirus vaccination uptake within the Swedish school-based vaccination programme: a population-based cohort study. Lancet Public Health. 2024. PMID: 39214636. doi:10.1016/S2468-2667(24)00182-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。